论文部分内容阅读
自１９９３年以来，国家医药管理局药品行政保护办公室发布受理公告已达２８件，其中１４种药品（原料和／或其制剂），即盐酸地拉普利（压得克）。奥曲肽（善得定）、苯磺酸氨氮地平（络活喜）、雷诺格拉斯蒂姆（格拉诺费特）、琥珀酸舒马坦（英明格）、头孢克肟（世福素）、非那甾胺（保列治）、Ｂ型嗜血杆菌组合疫苗（柏维协）、卡比多巴／左旋多巴（帕金宁控释片）、（神经妥乐平）、氯雷他定（克敏能）、盐酸曲匹西龙（呕必停）和头孢米诺钠己通过实质审查，符合行政保护条件，被授予保护证书。
Since 1993, the State Administration of Drug Protection Office of the State Pharmaceutical Administration has issued 28 notifications of acceptance, of which 14 kinds of drugs (raw materials and / or their preparations), namely delapril hydrochloride (pressure dex). Octreotide (good set), amminodipine besylate (Luo Huoxi), Raynaud Grass (Granofeta), succinic acid succinate (acetylene), cefixime (sevoflurane), non Naltrexone (Priech), Haemophilus influenzae type b combination vaccine (Berberis), carbidopa / levodopa (Parkinson’s controlled release tablets), (neurotropin), loratadine Ke Minneng), Circlip hydrochloride (vomit must stop) and cefminox sodium have passed the substantive examination, in line with the conditions of administrative protection, was awarded the certificate of protection.